Answer
Tagrisso (osimertinib mesylate) is contraindicated in anyone with hypersensitivity to its active substance or any of its excipients listed in section 6.1 of the product information.
Sources for this answer
- Tagrisso 40 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.3 Contraindications · Version 33Document updated
Sources checked